Somatropin biosimilar - Sandoz
Alternative Names: Omnitrope; PrOmnitropeLatest Information Update: 02 Oct 2021
At a glance
- Originator Sandoz
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Growth disorders; Prader-Willi syndrome; Short stature; Somatotropin deficiency; Turner's syndrome
- Registered Dwarfism
Most Recent Events
- 22 Jan 2021 Adhoc Somatropin clean up: MOA updated to Human growth hormone replacements based on https://meshb.nlm.nih.gov/record/ui?ui=D0193822
- 02 Sep 2015 Launched for Short stature (In adolescents, In children) in Canada (Parenteral)
- 02 Sep 2015 Launched for Turner's syndrome (In adolescents, In children) in Canada (Parenteral)